Kiora Pharmaceuticals, Inc. (KPRX) Stock

Kiora Pharmaceuticals, Inc. (KPRX) is a Healthcare stock trading at $2.58 (as of 2026-08-21), with a market capitalization of $11.44M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing treatments for ophthalmic diseases in the United States. Its pipeline includes KIO-301 for inherited and age-related degenerative retinal diseases, plus eye drop candidates KIO-101 and KIO-201 targeting inflammatory and postoperative ocular conditions.

Understand Kiora Pharmaceuticals, Inc.: how it makes money

Kiora Pharmaceuticals develops and commercializes therapies for ophthalmic diseases in the United States, with its main programs being KIO-301 (a photoswitch small molecule in Phase 1) and KIO-101 (an eye drop in Phase 2).

Its profit model is structurally tied to whether its ophthalmic drug candidates can advance through clinical trials (KIO-301 in Phase 1, KIO-101 in Phase 2) and reach successful commercialization, rather than to current, established product sales.

Business quality (Weak): Limited disclosure for this summary, with no reportable segments or operating KPI metrics provided, and financial snapshot showing 2024-06-30 revenue at 0.0B and a very negative operating margin.

Bull case

  • Vision-focused, mechanism-based lead asset: KIO-301 is in Phase 1 and is described as a photoswitch intended to restore vision in patients with inherited and age-related degenerative retinal diseases.
  • Multiple clinical-stage ophthalmic programs: The company is also developing KIO-101, an eye drop in Phase 2 for ocular presentation of rheumatoid arthritis and additional non-infectious indications (partially described).

Bear case

  • Early-stage clinical execution risk: Key programs are in Phase 1 and Phase 2, so outcomes depend on trial results before meaningful commercialization can occur.
  • Commercial momentum not evidenced in provided financial snapshot: The provided 2024-06-30 financial snapshot shows revenue at 0.0B, which implies no demonstrated revenue from products in this period based on the supplied data.
Valuation — source: SEC EDGAR (first-party)
Price$2.58
Market Cap$11.44M
Price / Book0.68
FCF Yield-75.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)-379.6%
FCF Growth (YoY)-217.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-9.00 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderADAR1 Capital Management, LLC ($324126.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOBrian Strem
Employees12
CountryUS
IPO Date2015-02-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • BioVie Inc. (BIVI)
  • Phio Pharmaceuticals Corp. (PHIO)
  • Moleculin Biotech, Inc. (MBRX)
  • Aspire Biopharma Holdings, Inc. (ASBP)
  • Bullfrog AI Holdings, Inc. Common Stock (BFRG)
  • Theriva Biologics, Inc. (TOVX)
  • MetaVia Inc. (MTVA)
  • Imunon, Inc. (IMNN)
KPRX earnings history · KPRX institutional & insider holders · KPRX KPIs & operating metrics · KPRX financials · KPRX investor presentations & press releases · KPRX SEC filings · KPRX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.